Phase I trial of IDX 19368.

Trial Profile

Phase I trial of IDX 19368.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 04 Feb 2013

At a glance

  • Drugs IDX 19368 (Primary)
  • Indications Hepatitis
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 04 Feb 2013 The development programme for IDX 19368 has been discontinued following a communication from the US FDA indicating that the programme will remain in clinical hold according to an Idenix media release. Patient dosing had not been initiated.
    • 04 Feb 2013 Status changed from suspended to discontinued based on information reported in an Idenix media release.
    • 27 Aug 2012 Status changed from planning to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top